Myriad Genetics
MYGN
221 hedge funds and large institutions have $640M invested in Myriad Genetics in 2025 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 75 increasing their positions, 71 reducing their positions, and 37 closing their positions.
586% more call options, than puts
Call options by funds: $954K | Put options by funds: $139K
33% more capital invested
Capital invested by funds: $480M → $640M (+$159M)
11% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 37
6% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 71
0% more funds holding
Funds holding: 221 → 221 (0)
3.03% less ownership
Funds ownership: 98.15% → 95.13% (-3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$8.86M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$5.81M |
| 3 |
AG
Algert Global
San Francisco,
California
|
+$5.42M |
| 4 |
Goldman Sachs
New York
|
+$5.16M |
| 5 |
RA
Royce & Associates
New York
|
+$3.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$8.16M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$6.76M |
| 3 |
KLP
Kent Lake PR
Anasco,
Puerto Rico
|
-$6.64M |
| 4 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$6.18M |
| 5 |
Morgan Stanley
New York
|
-$5.56M |
MYGN Hedge Fund Activity: Q3 2025 in Review
221 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q3 2025, worth a combined $640M — up 33% from $480M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new MYGN positions and 37 closed out — a net gain of 4 holders — while 75 added to existing stakes and 71 trimmed.
The largest buyer was Jacobs Levy Equity Management, adding an estimated $8.86M. The largest seller was Vanguard Group, cutting an estimated $8.16M.
- 221 institutional investors held Myriad Genetics (MYGN) as of Q3 2025, unchanged from Q2 2025.
- Funds reported $640M of Myriad Genetics stock for Q3 2025, up 33% quarter-over-quarter.
- 41 funds opened new Myriad Genetics positions in Q3 2025 and 37 closed out, a net change of +4 holders.
- The largest Myriad Genetics buyer in Q3 2025 was Jacobs Levy Equity Management, an estimated $8.86M added.
- The largest Myriad Genetics seller in Q3 2025 was Vanguard Group, an estimated $8.16M sold.
Based on aggregated 13F filings for Q3 2025.